

ENDING THE GUESSWORK IN CANCER CARE.

With a test that shows how cancer patient responds to immunotherapy drugs.

solidIO

Immunotherapy is powerful but still a guessing game

TODAY

$20B

BY 2030

x 5

Wasted on ineffective IO

We *predict* how cancer patients respond to immunotherapy *before* treatment starts.

solidIO

Billion-dollar IO pipelines still rely on models that don't predict human response.

>70% of IO trials fail in Phase II/III

Current models capture <20% of tumor–immune complexity

>$10B annually spent on ineffective IO candidates

→ Drug developers need a tool to evaluate drug response in complex **human-like** tumor-immune systems

solidIO

Solid IO reveals patient-specific treatment response in real time

Living clinical patient specimens



Tumor-on-chip with patients' native and systemic immunity to study immune activation and **single cell dynamics** with IO drugs and combinations*

Confident, timely decisions on IO use; Biomarker insights

solidIO

*Alsaed et al, Science Advances, 2024
*Kremneva et al, under revision

Our *ex vivo* model reveals critical interactions



1. **TUMOR VIABILITY**
   Does the tumor survive or die?

2. **IMMUNE ACTIVATION**
   Do immune cells respond?

3. **SINGLE-CELL RESOLUTION**
   What happens at the individual cell level?

solidIO

Focused Progress

POC*
WITH PHARMA
Oct 2024

"Ex vivo modeling of precision immuno-oncology responses in lung cancer"

Science Advances

ORION PHARMA

SPINOUT
Jan 2025

UNIVERSITY OF HELSINKI

€1.3 M
funding raised*

NORDIC SCIENCE INVESTMENTS

BSV VENTURES

eit Health

BUSINESS FINLAND

EP PerMed
European Partnership for Personalised Medicine

TODAY
Planning a clinical trial with major US hospitals

HUS Helsinki University Hospital

Test is able to predict chemotherapy resistance in clinical setting (Kremneva et al, under revision)

NEXT
Clinical validation and piloting with leading hospitals & pharma

* Patent pending

solidIO

Deep science. Serious execution.

NOORA HUJALA

CEO, Co-founder
EMBA, MSc (Health), BSc (Pharm)

Commercial operations and leadership in Pharma and Health business in startup, scaleup and transformation environments

Oriola FARENTA

HEIDI HAIKALA

CSO, Co-founder
PhD (Translational Cancer Biology), As. Professor & PI, MBA

Academic Lung cancer research and human-based models, and Medical Advisory in Pharma

HARVARD MEDICAL SCHOOL AMGEN Dana-Farber Cancer Institute

BASSEL ALSAED

Lead Scientist, Co-founder
MSc (Translational Medicine), PhD Candidate

Biomolecular and cancer research in academia

HUS A COLLABORATION BETWEEN HELSINKI UNIVERSITY HOSPITAL & UNIVERSITY OF HELSINKI
Stockholm University
UMEÅ UNIVERSITET

ROSS NELSON

Scientist
BSc (Cell and Molecular Biology)

Immunology and cancer research in academia, industry and start -up environments

EVOLVED THERAPEUTICS
UCD DUBLIN

solidIO

Looking for partnerships.

Let’s talk.

solidIO

www.solid-io.com heidi.haikala@solid-io.com +358-46-6597547